Audit 362506

FY End
2024-12-31
Total Expended
$7.78M
Findings
0
Programs
4
Year: 2024 Accepted: 2025-07-17

Organization Exclusion Status:

Checking exclusion status...

Findings

No findings recorded

Programs

ALN Program Spent Major Findings
93.395 Cancer Treatment Research $361,493 Yes 0
93.399 Cancer Control $284,516 Yes 0
93.394 Cancer Detection and Diagnosis Research $67,284 Yes 0
93.393 Cancer Cause and Prevention Research $17,511 Yes 0

Contacts

Name Title Type
PNQDLXQ6RGD5 Damien Mar Chong Auditee
2066529711 Andrew Van Ness Auditor
No contacts on file

Notes to SEFA

Title: Basis of Presentation Accounting Policies: Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following cost principles in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. De Minimis Rate Used: N Rate Explanation: CRAB has a negotiated indirect cost rate for use on federal grants and contracts. For 2024, the predetermined rate was 44% based on modified total direct costs. CRAB has elected not to use the 10 percent de minimis indirect cost rate allowed under the Uniform Guidance. The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal grant activity of Cancer Research And Biostatistics (CRAB) under programs of the federal government for the year ended December 31, 2024. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Because the Schedule presents only a selected portion of the operations of CRAB, it is not intended to and does not present the financial position, changes in net assets, or cash flows of CRAB.